Carvedilol inhibits clinical progression in patients with mild symptoms of heart failure. US Carvedilol Heart Failure Study Group. - Wikidata - awgldk - TriplyDB

Carvedilol inhibits clinical progression in patients with mild symptoms of heart failure. US Carvedilol Heart Failure Study Group.

Carvedilol inhibits clinical progression in patients with mild symptoms of heart failure. US Carvedilol Heart Failure Study Group.

http://www.wikidata.org/entity/Q42552227

about

Erythropoiesis-stimulating agents for anaemia in chronic heart failure patients Population pharmacokinetics of S(-)-carvedilol in healthy volunteers after administration of the immediate-release (IR) and the new controlled-release (CR) dosage forms of the racemate A Review of the External Validity of Clinical Trials with Beta-Blockers in Heart Failure Thirty Years of Evidence on the Efficacy of Drug Treatments for Chronic Heart Failure With Reduced Ejection Fraction: A Network Meta-Analysis Pharmacologic Update - Beta Blockers in Treatment of Heart Failure and Hypertension in Diabetes: Ugly Misconceptions Slain by Beautiful Clinical Data.Evaluation and treatment strategies in patients at high risk of sudden death post myocardial infarction.Effects of carvedilol on structural and functional outcomes and plasma biomarkers in the mouse transverse aortic constriction heart failure model.Relation of beta-blocker use with frequency of hospitalization for heart failure in patients with left ventricular diastolic dysfunction (from the Heart and Soul Study)Major beta blocker mortality trials in chronic heart failure: a critical review.Clinical Pharmacology of Carvedilol.Sympathetic activation and the role of beta-blockers in chronic heart failure.Novel treatment approaches in hypertensive type 2 diabetic patients Current issues regarding beta-adrenergic blockade in patients with congestive heart failure: patient selection, nonselective versus selective blockade, management of adverse effects, and indications for withdrawal of therapy.Beta-blockers and amiodarone for the primary prevention of sudden cardiac death.beta-blockers in heart failure: recently completed and ongoing clinical trials.beta-blocker therapy: a standard of care for heart failure.beta-Blockers in congestive heart failure.Beta blockers for CHF. Adrenergic blockade dramatically reduces morbidity and mortality.Digitalis for treatment of congestive heart failure in patients in sinus rhythm.Carvedilol versus other beta-blockers in heart failure.Economics of chronic heart failure.Impact of combined clenbuterol and metoprolol therapy on reverse remodelling during mechanical unloading.Clinical trials of antiarrhythmic drugs in postmyocardial infarction and congestive heart failure patients.Beta-blocker treatment in heart failure.Carvedilol in the failing heart.Role of race in the pharmacotherapy of heart failure.Surrogate end points in heart failure.The importance of early intervention in CHF--signs and symptom relief.β-Blockers for the prevention of sudden cardiac death in heart failure patients: a meta-analysis of randomized controlled trials Comparison of the epidemiology and co-morbidities of heart failure in the pediatric and adult populations: a retrospective, cross-sectional study.CHARITY: Chagas cardiomyopathy bisoprolol intervention study: a randomized double-blind placebo force-titration controlled study with Bisoprolol in patients with chronic heart failure secondary to Chagas cardiomyopathy [NCT00323973].[Cardiac sequelae of hypertension].Smad3 inactivation and MiR-29b upregulation mediate the effect of carvedilol on attenuating the acute myocardium infarction-induced myocardial fibrosis in rat.Contemporary use of beta receptor antagonists in chronic heart failure.Beta-blocker benefit according to severity of heart failure.Impact of concurrent amiodarone treatment on the tolerability and efficacy of carvedilol in patients with chronic heart failure.Effects of carvedilol on left ventricular remodelling in chronic stable heart failure: a cardiovascular magnetic resonance study.Selection of endpoints for heart failure clinical trials.Beta-blockade in heart failure: selective versus nonselective agents.Critical differences among beta-adrenoreceptor antagonists in myocardial failure: debating the MERIT of COMET.

P2860

Q24241045-1A49B59B-2910-4B8F-ABED-031FF8AA2C7D Q24647717-A884E834-238C-48D0-8DED-486062EF75CF Q28068618-BE36447F-6842-4CA0-BE90-68C1F933F3FE Q30239022-ED497135-160A-4818-ADB4-74CAAC8B3F91 Q30654695-FAE5E2AF-16FC-480A-987F-9685E8E58090 Q33175341-5E46F86B-360B-4619-ABA7-7E6F2616C5C6 Q33606538-3D58C6EA-4F6E-497F-8006-DFC379823FE5 Q33682749-B9A3C31A-8DF7-4FAB-98D2-E8903BE3EA83 Q33780871-805CC059-80F1-46AB-ACAF-B728C6DCEFDB Q33843419-AC4FA32E-FDC3-4D68-8B0B-511BDDE114B2 Q33951267-95D7249F-0E78-4D14-ADA9-57DAA517D058 Q34023579-9D77CFF8-753A-4A99-B05A-8C6C3DF59EBC Q34027213-7CFF3113-0215-4F5C-AFB8-0BBE0EE37F9B Q34027338-A5645C3B-77B1-4EBD-B2C5-368748F65267 Q34074729-8B0935AC-9BCD-4B1D-9F8E-11E7657E0C97 Q34088204-41DFCB64-4C45-454A-A46E-62789387EABD Q34119535-E050E460-5CC8-4C01-9EBA-73375DA7F5BC Q34193584-BDF1FFE9-E983-4904-9F2B-E822A6EE0D66 Q34202664-CEFD4DD6-CF15-4393-836B-BEE7D3D1E10A Q34232069-9FD3A443-3F2D-43BA-9DE1-148676A9F88A Q34264676-EACE10A5-03BE-4D3A-A276-630B6940B39B Q34275561-4609AAB8-C0B1-4E91-98E7-9390DAA0418B Q34308130-D3776C00-2E80-4293-A999-641332D4608B Q34316468-807FAB37-DB7B-41B5-9B7A-09536AC366B9 Q34478931-17251BCC-2106-4683-841C-3E494F8CD94B Q34564305-BEFEA49C-A268-435E-B088-A459F270EBE5 Q34564309-E7ED008C-E086-40E8-AE07-0D470C4691D6 Q34610087-00143EC2-1C98-480D-AC54-D3C3BB3001AA Q34815329-4E18267F-EF94-4DB0-B98C-7AF68364CDF4 Q34945026-3C3EABF3-9951-4B09-A859-674730C62AB2 Q34973539-05B6EE36-016A-47C6-AD0B-BFCCBA2A5797 Q34973985-F56CE6C3-A34F-45A5-958F-A16689B3D7D2 Q35005754-CC7F40A6-F24A-4939-A5A9-FB181D0CCED0 Q35036013-05D502C7-A43D-4324-80A7-0EF7AD556FAE Q35150702-7D9A3E4C-2345-43DE-A69A-533DAFE142DB Q35566637-C29C3AE6-1347-4761-9CBE-A1D69158783C Q35582518-592F322C-B2C6-4A3C-AD5C-625810BD2083 Q35607862-8B294E88-7FBC-4BA0-B51E-58F824DF6AB5 Q35631382-24ED09C1-A8B8-4723-9D79-9F054D5D1126 Q35985739-1827FD1B-7AC6-4ABC-9FBC-01E949383B86

P2860

Carvedilol inhibits clinical progression in patients with mild symptoms of heart failure. US Carvedilol Heart Failure Study Group.

http://www.wikidata.org/entity/Q42552227

description

1996 nî lūn-bûn

@nan

1996年の論文

@ja

1996年論文

@yue

1996年論文

@zh-hant

1996年論文

@zh-hk

1996年論文

@zh-mo

1996年論文

@zh-tw

1996年论文

@wuu

1996年论文

@zh

1996年论文

@zh-cn

name

Carvedilol inhibits clinical p ...... lol Heart Failure Study Group.

@en

Carvedilol inhibits clinical p ...... lol Heart Failure Study Group.

@nl

type

label

Carvedilol inhibits clinical p ...... lol Heart Failure Study Group.

@en

Carvedilol inhibits clinical p ...... lol Heart Failure Study Group.

@nl

prefLabel

Carvedilol inhibits clinical p ...... lol Heart Failure Study Group.

@en

Carvedilol inhibits clinical p ...... lol Heart Failure Study Group.

@nl

P1433

Q42552227-ADB8A856-59FF-4735-A7AA-F338250F8E3E

P1476

Q42552227-418C5A0B-8DEE-4640-9A81-C8CA50CD1627

P2093

Q42552227-08419729-7F5A-4329-A5F0-705B0917A0ED

Q42552227-1D36F2F1-5860-4F18-85EE-3DAE3FDA336B

Q42552227-325E7629-58CB-416C-B8A1-164193B55EEA

Q42552227-4653DB6A-84E3-4E91-8561-255E8B52A1E1

Q42552227-4D76778B-E461-432D-B283-D595914E3032

Q42552227-53BFE2A3-300C-4E75-AFEE-8A9BC903F339

Q42552227-60AD5C07-F1CB-4BC6-8A50-B5D9F784CC08

Q42552227-6C120E4A-92B1-43D6-9608-47CB721B33EF

Q42552227-A5842B6E-9FC2-4291-B2F7-61BAE43FD38C

Q42552227-AB72A350-04CD-4C05-B050-D326CE280166

P304

Q42552227-BF782739-D0DE-4B0D-84A9-D1346D7B2289

P31

Q42552227-8F2A7997-88F1-4616-8829-42E63E6218CA

P356

Q42552227-BF24E344-8C1F-4DC6-B01F-A6FB94FBFF2A

P407

Q42552227-BC280838-4440-4BAD-AAED-0EFBF7939512

P433

Q42552227-9313F72D-598A-4C3C-9A3F-F940767BA1A5

P478

Q42552227-23F380F8-65E7-4051-9483-C7D212828BBC

P577

Q42552227-D9D0DCFA-4F10-4E2C-8BAD-A571938E89C1

P698

Q42552227-7BFFBCF0-71B7-4D81-839E-796F1AC40B24

P921

Q42552227-BFEFCCE0-0F35-445A-8108-C3F204649FFF

P356

01.CIR.94.11.2800

P1433

P1476

Carvedilol inhibits clinical p ...... lol Heart Failure Study Group.

@en

P2093

B F Uretsky

http://www.w3.org/2001/XMLSchema#string

E M Gilbert

http://www.w3.org/2001/XMLSchema#string

J A Bowers

http://www.w3.org/2001/XMLSchema#string

J D Sackner-Bernstein

http://www.w3.org/2001/XMLSchema#string

J N Cohn

http://www.w3.org/2001/XMLSchema#string

M A Lukas

http://www.w3.org/2001/XMLSchema#string

M B Fowler

http://www.w3.org/2001/XMLSchema#string

M Packer

http://www.w3.org/2001/XMLSchema#string

M R Bristow

http://www.w3.org/2001/XMLSchema#string

R Hershberger

http://www.w3.org/2001/XMLSchema#string

P304

2800-2806

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1161/01.CIR.94.11.2800

http://www.w3.org/2001/XMLSchema#string

P407

P433

11

http://www.w3.org/2001/XMLSchema#string

P478

94

http://www.w3.org/2001/XMLSchema#string

P577

1996-12-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

8941105

http://www.w3.org/2001/XMLSchema#string

P921